As our ability to engage the immune system to combat disease becomes more advanced, the cancer treatment paradigm is changing. New immunotherapies require not only an exceptional clinical team, but also advanced patient monitoring mechanisms and care integration across multiple settings. ImmunoBridge facilitates the ability of community oncology practices to confidently and effectively manage their patients receiving the most promising immunotherapies available.

Immune-based treatments can be associated with unique toxicities and side effects that require careful and thorough patient monitoring and follow-up. Many of these treatments are subject to risk evaluation and mitigation strategies (REMS) that require additional planning, education, supervision, and data reporting. These programs are frequently administered across multiple care settings, which can be resource-intensive for many practices. ImmunoBridge seamlessly integrates these administration and recordkeeping processes across multiple sites, including potential admitting hospitals, to allow oncologists to focus more time and attention on caring for their patients.

Advanced immunotherapies can be expensive and may be associated with reimbursement complexities not generally encountered in the community oncology setting, requiring that practices take on additional financial risk to offer the most advanced treatment options. ImmunoBridge facilitates the acquisition of these therapies and takes on the responsibility of obtaining reimbursements, helping practices to minimize new financial risks and continue to direct their attention to supporting the cost of conventional cancer care.

To fully define the optimal role of these advanced immunotherapies in clinical practice, leading community oncology practices and their patients must be actively engaged in the clinical trial process. ImmunoBridge is positioned to interface with the most innovative drug manufacturers to offer impactful clinical trials to our partner practices, serving as the primary point of contact for study startup and management, regulatory submissions, data governance, and trial administration. We understand that the future of cancer care is patient-centric, personalized, and near-to-home, so keeping patients and their trusted oncologists united throughout the care continuum is at the center of our mission.